An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. will host a hybrid Investor & Analyst Event on September 19 to discuss the Company's clinical pipeline progress, strategic initiatives, and business outlook. In-person attendance is open to invited research analysts and institutional investors, while others can watch the live video webcast. Questions can be submitted through the webcast platform. A replay of the webcast will be available on the Company's website.
Positive
None.
Negative
None.
RADNOR, Pa.--(BUSINESS WIRE)--
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host a hybrid Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern Time in New York. The event will feature presentations from Marinus management and Key Opinion Leaders to discuss the Company’s clinical pipeline progress, strategic initiatives and business outlook.
In-person attendance is open to invited research analysts and institutional investors. All others are invited to watch the live video webcast. Live questions will be taken by in-person guests, and virtual participants may submit questions through the webcast platform.
To register for the video webcast, please visit the Investor Relations section of the Company's website at https://ir.marinuspharma.com/events-and-presentations/. A replay of the webcast will be archived on the Investor Relations section of the Company's website following the event.
About Marinus Pharmaceuticals
Marinus is a commercial stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit www.marinuspharma.com.
When will Marinus Pharmaceuticals host the Investor & Analyst Event?
Marinus Pharmaceuticals will host the Investor & Analyst Event on Tuesday, September 19.
What will be discussed at the event?
The event will cover Marinus Pharmaceuticals' clinical pipeline progress, strategic initiatives, and business outlook.
Who can attend the event in person?
In-person attendance is open to invited research analysts and institutional investors.
How can others participate in the event?
Others can watch the live video webcast and submit questions through the webcast platform.
Where can I register for the video webcast?
You can register for the video webcast on the Investor Relations section of Marinus Pharmaceuticals' website at https://ir.marinuspharma.com/events-and-presentations/.
Will there be a replay of the webcast?
Yes, a replay of the webcast will be archived on the Investor Relations section of Marinus Pharmaceuticals' website following the event.
